CR6736A - 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA - Google Patents

5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA

Info

Publication number
CR6736A
CR6736A CR6736A CR6736A CR6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
typosine
alquilpirido
piridines
kinasa
Prior art date
Application number
CR6736A
Other languages
Spanish (es)
Inventor
John Booth Richard
Myra Dobrusin Ellen
Laurence Toogood Peter
Norman Vanderwel Scott
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6736A publication Critical patent/CR6736A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos utiles para el tratamiento de trastornos de la proliferacion celular como cancer, arteroclerosis, y restenosis. Estos compuestos son inhibidores potentes de kinasas dependientes de ciclina y de kinasas reguladas por factores de crecimiento.It refers to compounds useful for the treatment of cell proliferation disorders such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin dependent kinases and kinases regulated by growth factors.

CR6736A 2000-03-06 2002-08-23 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA CR6736A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
CR6736A true CR6736A (en) 2004-03-10

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6736A CR6736A (en) 2000-03-06 2002-08-23 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA

Country Status (37)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
PY (1) PY0104899A (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
SK11322003A3 (en) * 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
EP1408985A4 (en) * 2001-06-21 2006-03-22 Ariad Pharma Inc Novel pyridopyrimidones and uses thereof
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
KR20040103972A (en) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 Novel Compounds
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
EP1590341B1 (en) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE602004017474D1 (en) * 2003-07-11 2008-12-11 Warner Lambert Co ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
UY29439A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
AU2006229995A1 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
PT1940839E (en) * 2005-10-07 2013-10-10 Exelixis Inc Pyridopyrimidinone inhibitors of pi3kalpha
HRP20130902T1 (en) * 2005-10-07 2013-11-08 Exelixis Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2663401C (en) 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
BRPI0715566A2 (en) * 2006-10-16 2013-07-02 Gpc Biotech Inc compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
UA101611C2 (en) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors
PL2168966T3 (en) * 2007-06-15 2017-06-30 Msd K.K. Bicycloaniline derivative
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ATE531372T1 (en) 2008-04-07 2011-11-15 Amgen Inc GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN102648200A (en) * 2009-10-09 2012-08-22 亚弗克希斯公司 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101754664B1 (en) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
UY33221A (en) 2010-02-09 2011-09-30 Univ California METHODS TO TREAT CANCER USING PI3K AND mTOR INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
PT2600719E (en) 2010-08-05 2014-12-22 Univ Temple 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
KR101606250B1 (en) 2011-03-23 2016-03-24 암젠 인크 Fused tricyclic dual inhibitors of cdk 4/6 and flt3
AU2012255860C1 (en) * 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
DK3431475T3 (en) * 2013-02-21 2021-05-25 Pfizer Solid forms of a selective CDK4 / 6 inhibitor
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105816437B (en) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 A pharmaceutical preparation of palbociclib and its preparation method
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN109803968A (en) 2016-08-15 2019-05-24 辉瑞公司 Pyridopyrimidinone CDK2/4/6 inhibitor
CN110809576B (en) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 FGFR kinase inhibitor and pharmaceutical use
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
US12358911B2 (en) 2018-12-07 2025-07-15 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as CDK-HDAC dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors
AU2022234998B2 (en) * 2021-03-08 2025-04-10 Jinan University Pyridopyrimidine compounds and applications thereof
JP7822578B2 (en) * 2021-06-09 2026-03-03 ティーワイケー メディシンズ（ジョンジョウ），インコーポレーテッド Compounds used as CDK kinase inhibitors and their applications
EP4588917A4 (en) * 2022-09-16 2026-06-17 Univ East China Normal PYRIDONOPYRIMID INDERIVATE AS AN RSK HIBITOR AND USE OF IT
CN120202198A (en) * 2022-11-10 2025-06-24 北京普祺医药科技股份有限公司 Sulfide compound with soft drug properties, pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2301194T3 (en) * 1997-02-05 2008-06-16 Warner-Lambert Company Llc PIRIDO 2,3-D PYRIMIDINS AND 4-AMINOPIRIMIDINAS AS INHIBITORS OF THE CELL PROLIFERATION.
DE69939168D1 (en) * 1998-05-26 2008-09-04 Warner Lambert Co BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELL REPRODUCTION

Also Published As

Publication number Publication date
AR034119A1 (en) 2004-02-04
NO20024235L (en) 2002-11-05
GT200100037A (en) 2002-03-04
ZA200207110B (en) 2003-12-04
YU66502A (en) 2005-09-19
SV2001000338A (en) 2001-11-30
SK12472002A3 (en) 2003-04-01
HUP0300136A2 (en) 2003-05-28
IL151480A0 (en) 2003-04-10
CN1422268A (en) 2003-06-04
PA8513201A1 (en) 2003-06-30
MA26881A1 (en) 2004-12-20
IS6524A (en) 2002-08-23
BR0109056A (en) 2003-06-03
AU2001233028A1 (en) 2001-10-03
OA12227A (en) 2004-03-18
HN2001000040A (en) 2001-09-06
BG107161A (en) 2003-06-30
KR20020075805A (en) 2002-10-05
AP2002002643A0 (en) 2002-12-31
PL358271A1 (en) 2004-08-09
CA2401368A1 (en) 2001-09-27
MXPA02008535A (en) 2002-12-13
EP1268476A1 (en) 2003-01-02
EA200200802A1 (en) 2003-02-27
PY0104899A (en) 2003-11-03
EE200200506A (en) 2004-02-16
NZ520962A (en) 2003-09-26
CZ20022929A3 (en) 2003-02-12
PE20011177A1 (en) 2001-11-23
HRP20020798A2 (en) 2004-02-29
TNSN01036A1 (en) 2005-11-10
WO2001070741A1 (en) 2001-09-27
JP2003528101A (en) 2003-09-24
DZ3308A1 (en) 2001-09-27
CO5280200A1 (en) 2003-05-30
NO20024235D0 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
AR030044A1 (en) PIRIDO (2,3-D) PIRIMIDIN-2,7-KINASE INHIBITING DIAMINS
GT200300087A (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
ECSP088145A (en) BICYCLIC DERIVATIVES AS INHIBITORS OF CINASA P38
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
BRPI0406809A (en) 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors
CR20130506A (en) PIRROL [2,3-b] PIRIDINES AND PIRROL [2,3-b] HETEROARILO PYRIMIDINES REPLACED AS INHIBITORS OF JANUS KINASES (DIVISIONAL EXP. 10065)
SV2002000572A (en) 2- (4-PIRIDIL) ANIMO- 6- DIALCOXIFENIL-PIRIDO [2,3-D] PIRIMIDIN-7-ONAS
ECSP045201A (en) 2- (PIRIDIN-2-ILAMINO) -PIRIDO [2,3-d] PIRIMIDIN-7-ONAS
MXPA04002983A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors.
CR9663A (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
UY27225A1 (en) INHIBITORS OF RHO-QUINASA
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
HN2002000067A (en) INHIBITORS OF THE RHO - QUINASA.
PT1467735E (en) Polymorphs of clopidogrel hydrogensulfate
PT1325011E (en) METHODS AND COMPOUNDS FOR TREATMENT OF PROLIFERATIVE DISEASES
GT200200190A (en) SUBSTITUTED BENZIMIDAZOL COMPOUNDS AND ITS USE IN CANCER TREATMENT
CR9568A (en) PIRIDO DERIVATIVES [2,3-d] PYRIMIDINE, ITS PREPARATION, ITS APPLICATION IN THERAPEUTICS
IL151692A0 (en) Polyamine analogues as cytotoxic agents
CR8749A (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMALO CELLULAR GROWTH
DE60100855D1 (en) 1,8-NAPHTHALIMID IMIDAZO [4,5,1-DE] ACRIDONE WITH ANTITUARY EFFECT
EP1615897A4 (en) Pyrimidinone compounds as calcilytics
UY26559A1 (en) PIRIDOL [2,3-D] PIRIMIDIN-2,7-DIAMINES KINASE INHIBITORS
UA81420C2 (en) Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase
CR7068A (en) NEW SPIROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE-7
ECSP982587A (en) PIRIDINE DERIVATIVES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)